Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials

Antonio Bernardo, Raffaella Palumbo, Rebecca Pedersini, Elena Rota Caremoli, Anna Rita Gambaro, Antonella Ferzi, Francesca Riva, Donatella Grasso, Marco Danova, Emiliana Tarenzi, Valter Torri, Marina E Cazzaniga

Research output: Contribution to journalArticlepeer-review


BACKGROUND: Few data are available regarding efficacy and safety of nanoparticle albumin-bound (nab)-paclitaxel in advanced breast cancer patients outside a controlled trial, especially for the weekly schedule.

PATIENTS AND METHODS: We prospectively collected data of advanced breast cancer patients who were candidates to be treated with weekly (125 mg/m(2) for 3 consecutive weeks followed by a 1-week rest) or every 3 weeks (260 mg/m(2)) schedules of nab-paclitaxel, according to physician's decision.

RESULTS: The study enrolled 209 patients, of whom 92 (39.3%) received weekly nab-paclitaxel. The median age was 58 (range, 31-84) years; 21.8% of the patients were classified as triple-negative breast cancer (estrogen-recetor/progesteron-receptor-negative). The median number of cycles was 5.5. The overall response rate was 32.1% in the whole population, without any significant difference according to schedule, previous paclitaxel exposure, presence of visceral metastases, or line of treatment. The median time to disease progression was 6 months (95% confidence interval, 1-34), with no differences according to the schedule of treatment. Severe adverse events (Grade 3-4) were observed in 60.6% of the patients. The main toxicities were alopecia (53.4%), neutropenia (3%), and sensory neuropathy (2.1%).

CONCLUSION: Our real-life data indicate that both schedules of nab-paclitaxel are manageable and safe in advanced breast cancer patients, even if previously treated with other taxanes.

Original languageEnglish
Pages (from-to)433-440
Number of pages8
JournalClinical Breast Cancer
Issue number6
Publication statusPublished - Oct 2017


  • Journal Article

Fingerprint Dive into the research topics of 'Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials'. Together they form a unique fingerprint.

Cite this